Navigation Links
Cylex Announces Valuable Personnel Additions

COLUMBIA, Md., March 16 /PRNewswire/ -- Cylex™, a global life science company that develops and manufactures in vitro diagnostic products based on patented technology, announced today the expansion of its growing staff with the hiring of Chari-Beth White, Marc Mendels and Julie Fudoli as well as the promotion of James E. "Jim" Brosius.

(Logo: )

"Due to the Company's rapid business development and growth in 2009, we are pleased to announce expansion of our presence throughout North America and abroad. In order to meet our infrastructure development goals, we are extremely pleased that these talented individuals are now with Cylex," said Jack Kromar, Vice President, Sales and Marketing.

Chari Beth White brings significant experience to Cylex as National Sales Manager – over 18 years of progressive sales/marketing and management experience with several major U.S. biotechnology research and pharmaceutical corporations including Gilead Sciences, Inc., Agouron Pharmaceuticals, Pharmacia & Upjohn, and Schering-Plough Pharmaceuticals. Chari Beth will assume responsibility for the direct management and leadership of field-based Business Development Managers. She will deliver sales and market share objectives, develop and execute the Cylex sales plan, and assist by providing solutions that meet customer needs.

Marc Mendels begins his role of Medical Science Liaison (MSL) and comes with extensive experience as a Senior MSL from Astellas and Wyeth Pharmaceuticals, over 16 years of experience in the transplant market, and sales experience from Schering-Plough and Johnson & Johnson. As an MSL, Marc will be a field-based member of the Medical Affairs support team responsible for the application of scientific knowledge and experience to organize the collection of and to analyze clinical data; educate physicians and transplant coordinators; and to establish and maintain clinical/scientific relationships with key opinion leaders, researchers, transplant coordinators, laboratory managers, and other members of the scientific community.

Julie Fudoli joins Cylex as a Business Development Manager, and has over 14 years of experience in sales and sales management. She successfully developed and managed the CVS/Caremark transplant team as the National Transplant Manager for CVS/Caremark and has also been involved with the transplant community as the National Board Treasurer of the Transplant Recipient International Organization (TRIO) and a member of the National Foundation for Transplant (NFT). Julie will continue to build strong business relationships with clinical decision makers and the consumers of our products.

"These individuals further strengthen the Sales and Medical Affairs teams at Cylex, and also complement the newly created position, Manager, International Sales and Marketing filled by recently promoted Jim Brosius," added Kromar.

James ("Jim") E. Brosius was promoted to International Manager, Sales and Marketing and will focus on and grow Cylex international business, since Cylex continues to see increasing interest and demand in international markets for ImmuKnow. Jim has a thorough understanding of the value of ImmuKnow in transplantation, a significant depth of knowledge within the transplant field, and a demonstrated ability to communicate and build relationships with key opinion leaders and clinicians. Jim's focus on our international opportunities will accelerate Cylex's ability to increase the global use and sales of ImmuKnow.

According to Kromar, "Today marks another very exciting moment at Cylex. The growth that we experienced both within our sales and staff expansion has catapulted us within the transplant market. Each of our new and promoted employees dramatically enhances our ability to foster continued innovation and business development in transplantation."

About Cylex, Inc.

Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit

SOURCE Cylex, Inc.

Back to top



SOURCE Cylex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Cylex Announces Brad L. Stewart as President of the Company
3. Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications
4. Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):